$-0.42 EPS Expected for Seattle Genetics, Inc. (SGEN)

October 13, 2017 - By reb123z

 $ 0.42 EPS Expected for Seattle Genetics, Inc. (SGEN)
Investors sentiment decreased to 1.3 in 2017 Q2. Its down 0.20, from 1.5 in 2017Q1. It fall, as 30 investors sold Seattle Genetics, Inc. shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported.
Aperio Grp Lc reported 31,693 shares. Sumitomo Mitsui Trust invested 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). State Street has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Laurion Cap Management Lp accumulated 5,550 shares. Bank & Trust Of New York Mellon invested in 0.01% or 426,129 shares. Spark Inv Mgmt Ltd stated it has 139,100 shares. Deutsche National Bank Ag stated it has 801,493 shares. 830,806 are owned by Geode Cap Ltd Limited Liability Company. Jgp Glob Gestao De Recursos Ltda holds 19,634 shares. Baker Bros Advsr L P reported 45.73 million shares. The Pennsylvania-based Susquehanna Interest Group Incorporated Llp has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Capstone Asset Management Com holds 0.01% or 5,035 shares. Oppenheimer Asset Mngmt Incorporated stated it has 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Primecap Mgmt Co Ca owns 12.96M shares for 0.58% of their portfolio. Lpl Financial Limited Liability Company has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN).

Since May 5, 2017, it had 0 buys, and 3 insider sales for $2.20 million activity. SIEGALL CLAY B sold $892,897 worth of stock or 14,462 shares.

Analysts expect Seattle Genetics, Inc. (NASDAQ:SGEN) to report $-0.42 EPS on October, 26.They anticipate $0.19 EPS change or 82.61 % from last quarter’s $-0.23 EPS. After having $-0.39 EPS previously, Seattle Genetics, Inc.’s analysts see 7.69 % EPS growth. The stock increased 0.49% or $0.3 during the last trading session, reaching $61.77. About 1.99 million shares traded or 82.57% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since October 13, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Among 16 analysts covering Seattle Genetics (NASDAQ:SGEN), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Seattle Genetics had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by Oppenheimer on Monday, June 26. The firm has “Buy” rating by William Blair given on Tuesday, August 25. The rating was upgraded by Piper Jaffray to “Neutral” on Friday, October 30. The rating was maintained by Oppenheimer with “Hold” on Wednesday, August 16. The company was maintained on Tuesday, August 29 by Cantor Fitzgerald. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Cantor Fitzgerald on Monday, June 26. The firm has “Neutral” rating by Credit Suisse given on Monday, December 12. The rating was maintained by Cowen & Co with “Hold” on Monday, June 19. The rating was initiated by Morgan Stanley on Wednesday, September 7 with “Overweight”. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has market cap of $8.83 billion. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. It currently has negative earnings. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate .

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Businesswire.com which released: “Seattle Genetics to Host Conference Call and Webcast Discussion of Third …” on October 05, 2017, also Streetinsider.com with their article: “Seattle Genetics (SGEN) & Astellas Commences Pivotal Trial of Enfortumab Vedotin” published on October 10, 2017, Seekingalpha.com published: “Seattle Genetics: Good Time To Buy Based On Adcetris Label Expansion” on September 15, 2017. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Nasdaq.com and their article: “Seattle Genetics’ Adcetris Gets Breakthrough Therapy Status” published on October 03, 2017 as well as Nasdaq.com‘s news article titled: “Seattle Genetics Inks Clinical Collaborations for Cancer Drug” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: